In retrospective laboratory analyses, the authors found that the sFLT1-PlGF ratio decreased after initiation of eculizumab and they hypothesized that eculizumab may have moderated the antiangiogenic activity in preeclampsia (174). This evidence concerns the gene PGF and preeclampsia.